Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration

被引:66
作者
Krueger, WA
Schroeder, TH
Hutchison, M
Hoffmann, E
Dieterich, HJ
Heininger, A
Erley, C
Wehrle, A
Unertl, K
机构
[1] Univ Tubingen Hosp, Dept Anesthesiol, Tubingen, Germany
[2] Univ Tubingen Hosp, Dept Internal Med, Tubingen, Germany
[3] Zeneca Pharmaceut, Macclesfield, Cheshire, England
关键词
D O I
10.1128/AAC.42.9.2421
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics of meropenem were studied in nine anuric critically iii patients treated by continuous venovenous hemodiafiltration. Peak levels after infusion of 1,000 mg over 30 min amounted to 103.2 +/- 45.9 mu g/ml, and trough levels at 12 h were 9.6 +/- 3.8 mu g/ml. A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms. Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with loner clearances are applied.
引用
收藏
页码:2421 / 2424
页数:4
相关论文
共 24 条
[1]   MODFIT - A PHARMACOKINETICS COMPUTER-PROGRAM [J].
ALLEN, GD .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (06) :477-498
[2]   THE PHARMACOKINETICS OF MEROPENEM IN VOLUNTEERS [J].
BAX, RP ;
BASTAIN, W ;
FEATHERSTONE, A ;
WILKINSON, DM ;
HUTCHISON, M ;
HAWORTH, SJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 :311-320
[3]   PHARMACOKINETICS OF MEROPENEM IN PATIENTS WITH INTRAABDOMINAL INFECTIONS [J].
BEDIKIAN, A ;
OKAMOTO, MP ;
NAKAHIRO, RK ;
FARINO, J ;
HESELTINE, PNR ;
APPLEMAN, MD ;
YELLIN, AE ;
BERNE, TV ;
GILL, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :151-154
[4]  
BURMAN LA, 1991, J ANTIMICROB CHEMOTH, V27, P219
[5]   PHARMACOKINETICS OF MEROPENEM IN PATIENTS WITH VARIOUS DEGREES OF RENAL-FUNCTION, INCLUDING PATIENTS WITH END-STAGE RENAL-DISEASE [J].
CHIMATA, M ;
NAGASE, M ;
SUZUKI, Y ;
SHIMOMURA, M ;
KAKUTA, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :229-233
[6]   PHARMACOKINETICS OF MEROPENEM IN SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRMENT [J].
CHRISTENSSON, BA ;
NILSSONEHLE, I ;
HUTCHISON, M ;
HAWORTH, SJ ;
OQVIST, B ;
NORRBY, SR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (07) :1532-1537
[7]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[8]  
EDWARDS JR, 1995, J ANTIMICROB CHEMOTH, V36, P1
[9]   STABILITY OF MEROPENEM AND EFFECT OF 1-BETA-METHYL SUBSTITUTION ON ITS STABILITY IN THE PRESENCE OF RENAL DEHYDROPEPTIDASE-I [J].
FUKASAWA, M ;
SUMITA, Y ;
HARABE, ET ;
TANIO, T ;
NOUDA, H ;
KOHZUKI, T ;
OKUDA, T ;
MATSUMURA, H ;
SUNAGAWA, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (07) :1577-1579
[10]   CONTINUOUS ARTERIOVENOUS HEMOFILTRATION IN ACUTE RENAL-FAILURE [J].
GOLPER, TA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1985, 6 (06) :373-386